TEVA · Teva Pharmaceutical Industries Ltd · Webcasts, Transcripts & Audio
Market Cap
$45.67B
Shares
1.17B
Volume · Oct 2
4.77M
Avg daily vol (3M)
5.34M
Teva Pharmaceutical Industries Ltd Webcasts
Earnings calls, investor updates, investor days and conferences for Teva Pharmaceutical Industries Ltd (TEVA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼5.3%
$3.88B
−$1.30B
'22 Q4
23-02-08
▲0%
$3.66B
−$220.00M
'23 Q1
23-05-10
▲2.4%
$3.88B
−$872.00M
'23 Q2
23-08-02
▲7.1%
$3.85B
$69.00M
'23 Q3
23-11-08
▲14.8%
$4.46B
$464.00M
'23 Q4
24-01-31
▲4.3%
$3.82B
−$139.00M
'24 Q1
24-05-08
▲7.4%
$4.16B
−$846.00M
'24 Q2
24-07-31
▲12.5%
$4.33B
−$437.00M
'24 Q3
24-11-06
▼5.1%
$4.23B
−$217.00M
'24 Q4
25-01-29
▲1.9%
$3.89B
$214.00M
'25 Q1
25-05-07
▲0.3%
$4.18B
$282.00M
'25 Q2
25-07-30
▲3.4%
$4.48B
$433.00M
'25 Q3
25-11-05
▼64.5%
$1.50B
$481.00M
'25 Q4
26-01-28
▲2.3%
$3.98B
$369.00M
'26 Q1
26-04-29
LATEST
▼0.8%
$4.14B
−$576.00M
'26 Q2
26-07-29
Earnings call
FY26 · Q3
2026-11-03
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-23
Teva Pharmaceutical Industries Ltd (TEVA) September 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-22
Teva Pharmaceutical Industries Ltd (TEVA) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-22
Teva Pharmaceutical Industries Ltd (TEVA) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Teva Pharmaceutical Industries Ltd (TEVA) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-29
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Transcript
Confident tone
Pipeline launches (olanzapine, Ecopipam) and milestones
Innovative portfolio growth (Austedo, Ajovy, Uzedy)
Schizophrenia / LAI market opportunity
Revenue
$4.14B
▼ 0.8% YoY Diluted EPS
$-0.49
▼ 304.2% YoY Gross margin
52.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Teva Pharmaceutical Industries Ltd (TEVA) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Transcript
Confident tone
Innovative Portfolio Growth (AUSTEDO, UZEDY, AJOVY)
Emalex Bioscience Acquisition / Ecopipam
R&D Pipeline and Readouts
Revenue
$3.98B
▲ 2.3% YoY Diluted EPS
$0.31
▲ 72.2% YoY Gross margin
49.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Teva Pharmaceutical Industries Ltd (TEVA) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-01-28
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2025 Earnings Call Transcript
Confident tone
Innovative portfolio growth
Pipeline and R&D execution
Business development and capital allocation
Revenue
$1.50B
▼ 64.5% YoY Gross margin
177.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Transcript
Confident tone
Innovative portfolio growth engines (AUSTEDO, UZEDY, AJOVY)
AUSTEDO CMS price negotiation and 2027 targets
Cost savings program and operational efficiency
Revenue
$4.48B
▲ 3.4% YoY Diluted EPS
$0.37
Gross margin
51.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2025 Earnings Call Transcript
Confident tone
Innovative portfolio growth
Generics business performance
R&D pipeline and innovation
Revenue
$4.18B
▲ 0.3% YoY Diluted EPS
$0.24
Gross margin
50.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Transcript
Confident tone
Innovative brands growth
Long-acting injectable franchise in schizophrenia
2027 strategic targets and Pivot to Growth
Revenue
$3.89B
▲ 1.9% YoY Diluted EPS
$0.18
Gross margin
48.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2025-02-24
Teva Pharmaceutical Industries Ltd (TEVA) February 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-01-29
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Transcript
Confident tone
Financial performance and guidance
Innovative medicines (AUSTEDO, AJOVY, UZEDY)
Late-stage pipeline
Revenue
$4.23B*
▼ 5.1% YoY Gross margin
50.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Transcript
Confident tone
Innovative portfolio growth (AUSTEDO, AJOVY, UZEDY)
TAPI divestment
Generics business
Revenue
$4.33B
▲ 12.5% YoY Diluted EPS
$-0.39
▼ 750% YoY Gross margin
49.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Transcript
Confident tone
R&D pipeline progress (Olanzapine, TL1A, ICS/SABA, MSA)
AUSTEDO performance and IRA considerations
Innovative portfolio: AJOVY, UZEDY, SIMLANDI
Revenue
$4.16B
▲ 7.4% YoY Diluted EPS
$-0.75
Gross margin
48.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2024 Earnings Call Transcript
Confident tone
Biosimilars Launches and Outlook
AUSTEDO Growth and Guidance
Olanzapine LAI Phase III Results
Revenue
$3.82B
▲ 4.3% YoY Diluted EPS
$-0.12
Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-31
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2023 Earnings Call Transcript
Confident tone
Innovative brands: Austedo and Ajovy
New product launches (Uzedy, biosimilars)
Pivot to Growth strategy execution and 2023 results
Revenue
$4.46B*
▲ 14.8% YoY Gross margin
54.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2023 Earnings Call
Revenue
$3.85B
▲ 7.1% YoY Diluted EPS
$0.06
▲ 20% YoY Gross margin
48.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2023 Earnings Call
Revenue
$3.88B
▲ 2.4% YoY Diluted EPS
$-0.78
Gross margin
46.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2023 Earnings Call
Revenue
$3.66B
▲ 0% YoY Diluted EPS
$-0.20
Gross margin
43.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2022 Earnings Call
Revenue
$3.88B*
▼ 5.3% YoY Diluted EPS
$-1.17
Gross margin
45.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2022 Earnings Call
Revenue
$3.60B
▼ 7.5% YoY Diluted EPS
$0.05
▼ 80.8% YoY Gross margin
46.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2022 Earnings Call
Revenue
$3.79B
▼ 3.2% YoY Diluted EPS
$-0.23
▼ 221.1% YoY Gross margin
47.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2022 Earnings Call
Revenue
$3.66B
▼ 8.1% YoY Diluted EPS
$-0.86
▼ 1328.6% YoY Gross margin
47.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-09
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2021 Earnings Call
Revenue
$4.10B*
▼ 8% YoY Gross margin
50.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2021 Earnings Call
Revenue
$3.89B
▼ 2.3% YoY Diluted EPS
$0.26
Gross margin
46.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2021 Earnings Call
Revenue
$3.91B
▲ 1% YoY Diluted EPS
$0.19
▲ 46.2% YoY Gross margin
47.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2021 Earnings Call
Revenue
$3.98B
▼ 8.6% YoY Diluted EPS
$0.07
▲ 16.7% YoY Gross margin
47.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2020 Earnings Call
Revenue
$4.45B
▼ 0.3% YoY Diluted EPS
$0.14
▲ 40% YoY Gross margin
46.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2020 Earnings Call
Revenue
$3.98B
▼ 2.8% YoY Diluted EPS
$-3.97
Gross margin
46.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2020 Earnings Call
Revenue
$3.87B
▼ 7.3% YoY Diluted EPS
$0.13
Gross margin
45.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2020 Earnings Call
Revenue
$4.36B
▲ 5% YoY Diluted EPS
$0.06
Gross margin
47.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-12
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2019 Earnings Call
Revenue
$4.47B
▲ 1.1% YoY Diluted EPS
$0.10
Gross margin
43.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–35 of 35 webcasts
Key facts
CIK
818686
CUSIP
881624209
13F (30d)
13 filings
11 filers
Visit website
Investor relations